Marcie Glicksman, Ph.D. is the Chief Scientific Officer at Orig3n, Inc.; a biotechnology company that has established the world’s largest uniformly consented HLA-matched cell repository to be used to better understand the cellular and molecular foundations of disease. Dr. Glicksman has been in the field of drug discovery for more than 20 years.  Previously, Dr. Glicksman was a Professor at Harvard Medical School and Co-Director of the Laboratory for Drug Discovery in Neurodegeneration (LDDN). While at LDDN, she helped spin out 8 new therapeutic companies, one that now has a commercial product.  Previous to academics, she was in the biopharmaceutical industry for 13 years. This included leading programs for neurodegenerative diseases including co-inventorship of CEP1347, a drug candidate that has been in Phase III clinical trials.  She is involved in foundations including the Alzheimer’s Drug Discovery Foundation (ADDF) and reviews grants for NIH, and Department of Defense.  Dr. Glicksman co-founded the Academic Drug Discovery Consortium as a way to build a collaborative network for the academic drug discovery community. Dr. Glicksman received a bachelor’s degree from Brown University and a Ph.D. degree in Neuroscience from Washington University.  Dr. Glicksman has over 75 publications and 12 issued patents.